Latest news with #GBP1.4
Yahoo
23-05-2025
- Business
- Yahoo
Johnson Matthey PLC (JMPLF) Full Year 2025 Earnings Call Highlights: Strategic Divestment and ...
Revenue: Sales increased by 50% in Catalyst Technologies. Operating Margin: Catalyst Technologies margin improved from 7% to 14%; Clean Air margin increased to almost 12% this year, with expectations to reach mid-teens by year-end. EBITDA: Catalyst Technologies had a GBP30 million EBITDA three years ago. Net Sale Proceeds: GBP1.8 billion from the sale of Catalyst Technologies, with GBP1.6 billion net proceeds after taxes and costs. Shareholder Returns: GBP1.4 billion to be returned to shareholders, equating to GBP8 per share based on the previous day's share price. Net Debt: Reduced to GBP799 million, with a leverage ratio of 1.4 times. Free Cash Flow: Positive free cash flow for the year, with a GBP400 million improvement from the first half to the second half. Dividend: Maintained at 7p, totaling GBP130 million for the year. Clean Air Sales Decline: Sales down 8% due to global automotive production environment. PGM Profitability: Nearly doubled in the second half. Hydrogen Losses: Halved in the second half, moving towards breakeven. CapEx: GBP1.25 billion spent over the last four years, with plans to reduce significantly post-refinery completion. Cash Returns Commitment: GBP200 million annually from '26/'27 onwards. Future Sales Projections: Clean Air sales expected to exceed GBP2 billion by '27/'28; PGM sales projected at GBP450 million by '27/'28. Warning! GuruFocus has detected 6 Warning Signs with JMPLF. Release Date: May 22, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Johnson Matthey PLC (JMPLF) announced the sale of its Catalyst Technologies business to Honeywell for GBP1.8 billion, a significant valuation compared to previous offers. The company has significantly improved its Clean Air business, increasing margins from 8% to nearly 12%, with expectations to reach 16-18% by 2027/28. Johnson Matthey PLC (JMPLF) plans to return GBP1.4 billion to shareholders from the Catalyst Technologies sale proceeds. The new world-class refinery for Platinum Group Metals (PGM) is on track, expected to enhance cash generation and operational efficiency. The company has committed to delivering GBP200 million in cash returns to shareholders annually from 2026/27 onwards, supported by strong free cash flow projections. The transition to the new PGM refinery will incur additional costs and lower metal recoveries during the commissioning phase, impacting short-term profitability. The hydrogen market has underperformed expectations, leading to asset impairments and a delay in profitability. Clean Air sales have been affected by a decline in global automotive production, impacting revenue growth. The company faces challenges in reducing central costs and stranded costs following the sale of Catalyst Technologies. Johnson Matthey PLC (JMPLF) has experienced a high level of one-off items impacting financial results, including restructuring costs and asset write-downs. Q: Why is the timeline for the completion of the Catalyst Technologies sale set for the first half of 2026, and are there any key regulatory approvals required? A: The timeline is dependent on regulatory approvals, primarily from the US, Europe, and China. Given the minimal overlap between Johnson Matthey and Honeywell's businesses, the process is expected to be straightforward. The timeline has been agreed upon with Honeywell as a reasonable estimate. - Liam Condon, CEO Q: What are the plans for reducing central costs following the sale of Catalyst Technologies? A: Currently, about GBP15 million of central costs are charged to Catalyst Technologies. Post-sale, we aim to reduce these costs by improving processes across all areas, including finance, HR, and IT, to align with the smaller size of the group. - Richard Pike, CFO Q: Why was Hydrogen Technologies not included in the Catalyst Technologies sale to Honeywell? A: Hydrogen Technologies was integrated into Clean Air due to customer overlap and to benefit from shared overheads. This restructuring was necessary as the growth in hydrogen was not as initially forecasted. - Liam Condon, CEO Q: Can you provide an update on the new PGM refinery and how you plan to ensure a smooth transition from the old to the new plant? A: We are still in the construction phase and expect to begin commissioning at the end of this year or early next year. The transition will be gradual, with metal streams being moved one at a time to ensure a smooth start-up. We have extensive plans and expert teams in place to manage this process. - Liam Condon, CEO Q: What is the expected cash impact of the new refinery on PGMS from 2025/26 to 2027/28? A: During the transition, there will be increased depreciation and dual running costs, but these will be offset by the new refinery's efficiency and capacity to process higher volumes and more complex feeds, leading to improved margins and cash flow in the long term. - Richard Pike, CFO Q: Is the GBP250 million free cash flow target for 2027/28 clean, and does it include any net working capital realization? A: Yes, the GBP250 million target is clean free cash flow, excluding any net working capital realization. It reflects normalized profitability with ongoing operational improvements and lower levels of CapEx. - Richard Pike, CFO Q: What are the revenue expectations for Clean Air to achieve the 16% to 18% margin target by 2027/28? A: We expect Clean Air to generate over GBP2 billion in sales by 2027/28, with 90% of this already secured. The focus will be on maintaining high market shares and improving operational efficiency to achieve the margin target. - Anish Taneja, Chief Executive, Clean Air Q: How will the sale of Catalyst Technologies impact Johnson Matthey's strategic focus and financial outlook? A: The sale allows us to focus on our core competencies in PGMS and Clean Air, enhancing our ability to generate cash and commit to shareholder returns. We expect to deliver GBP200 million in cash returns annually from 2026/27 onwards. - Liam Condon, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
Johnson Matthey PLC (JMPLF) Full Year 2025 Earnings Call Highlights: Strategic Divestment and ...
Revenue: Sales increased by 50% in Catalyst Technologies. Operating Margin: Catalyst Technologies margin improved from 7% to 14%; Clean Air margin increased to almost 12% this year, with expectations to reach mid-teens by year-end. EBITDA: Catalyst Technologies had a GBP30 million EBITDA three years ago. Net Sale Proceeds: GBP1.8 billion from the sale of Catalyst Technologies, with GBP1.6 billion net proceeds after taxes and costs. Shareholder Returns: GBP1.4 billion to be returned to shareholders, equating to GBP8 per share based on the previous day's share price. Net Debt: Reduced to GBP799 million, with a leverage ratio of 1.4 times. Free Cash Flow: Positive free cash flow for the year, with a GBP400 million improvement from the first half to the second half. Dividend: Maintained at 7p, totaling GBP130 million for the year. Clean Air Sales Decline: Sales down 8% due to global automotive production environment. PGM Profitability: Nearly doubled in the second half. Hydrogen Losses: Halved in the second half, moving towards breakeven. CapEx: GBP1.25 billion spent over the last four years, with plans to reduce significantly post-refinery completion. Cash Returns Commitment: GBP200 million annually from '26/'27 onwards. Future Sales Projections: Clean Air sales expected to exceed GBP2 billion by '27/'28; PGM sales projected at GBP450 million by '27/'28. Warning! GuruFocus has detected 6 Warning Signs with JMPLF. Release Date: May 22, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Johnson Matthey PLC (JMPLF) announced the sale of its Catalyst Technologies business to Honeywell for GBP1.8 billion, a significant valuation compared to previous offers. The company has significantly improved its Clean Air business, increasing margins from 8% to nearly 12%, with expectations to reach 16-18% by 2027/28. Johnson Matthey PLC (JMPLF) plans to return GBP1.4 billion to shareholders from the Catalyst Technologies sale proceeds. The new world-class refinery for Platinum Group Metals (PGM) is on track, expected to enhance cash generation and operational efficiency. The company has committed to delivering GBP200 million in cash returns to shareholders annually from 2026/27 onwards, supported by strong free cash flow projections. The transition to the new PGM refinery will incur additional costs and lower metal recoveries during the commissioning phase, impacting short-term profitability. The hydrogen market has underperformed expectations, leading to asset impairments and a delay in profitability. Clean Air sales have been affected by a decline in global automotive production, impacting revenue growth. The company faces challenges in reducing central costs and stranded costs following the sale of Catalyst Technologies. Johnson Matthey PLC (JMPLF) has experienced a high level of one-off items impacting financial results, including restructuring costs and asset write-downs. Q: Why is the timeline for the completion of the Catalyst Technologies sale set for the first half of 2026, and are there any key regulatory approvals required? A: The timeline is dependent on regulatory approvals, primarily from the US, Europe, and China. Given the minimal overlap between Johnson Matthey and Honeywell's businesses, the process is expected to be straightforward. The timeline has been agreed upon with Honeywell as a reasonable estimate. - Liam Condon, CEO Q: What are the plans for reducing central costs following the sale of Catalyst Technologies? A: Currently, about GBP15 million of central costs are charged to Catalyst Technologies. Post-sale, we aim to reduce these costs by improving processes across all areas, including finance, HR, and IT, to align with the smaller size of the group. - Richard Pike, CFO Q: Why was Hydrogen Technologies not included in the Catalyst Technologies sale to Honeywell? A: Hydrogen Technologies was integrated into Clean Air due to customer overlap and to benefit from shared overheads. This restructuring was necessary as the growth in hydrogen was not as initially forecasted. - Liam Condon, CEO Q: Can you provide an update on the new PGM refinery and how you plan to ensure a smooth transition from the old to the new plant? A: We are still in the construction phase and expect to begin commissioning at the end of this year or early next year. The transition will be gradual, with metal streams being moved one at a time to ensure a smooth start-up. We have extensive plans and expert teams in place to manage this process. - Liam Condon, CEO Q: What is the expected cash impact of the new refinery on PGMS from 2025/26 to 2027/28? A: During the transition, there will be increased depreciation and dual running costs, but these will be offset by the new refinery's efficiency and capacity to process higher volumes and more complex feeds, leading to improved margins and cash flow in the long term. - Richard Pike, CFO Q: Is the GBP250 million free cash flow target for 2027/28 clean, and does it include any net working capital realization? A: Yes, the GBP250 million target is clean free cash flow, excluding any net working capital realization. It reflects normalized profitability with ongoing operational improvements and lower levels of CapEx. - Richard Pike, CFO Q: What are the revenue expectations for Clean Air to achieve the 16% to 18% margin target by 2027/28? A: We expect Clean Air to generate over GBP2 billion in sales by 2027/28, with 90% of this already secured. The focus will be on maintaining high market shares and improving operational efficiency to achieve the margin target. - Anish Taneja, Chief Executive, Clean Air Q: How will the sale of Catalyst Technologies impact Johnson Matthey's strategic focus and financial outlook? A: The sale allows us to focus on our core competencies in PGMS and Clean Air, enhancing our ability to generate cash and commit to shareholder returns. We expect to deliver GBP200 million in cash returns annually from 2026/27 onwards. - Liam Condon, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
06-02-2025
- Business
- Yahoo
GSK PLC (GSK) Q4 2024 Earnings Call Highlights: Strong Specialty Medicines Drive Growth Amid ...
Sales Growth: Increased by 8% to over GBP31 billion. Core Operating Profit: Up 13%. Core EPS: Increased by 12%. Dividend: Increased to 61p per share. Specialty Medicines Growth: Up 19% in 2024. Oncology Sales: Nearly doubled to more than GBP1.4 billion. HIV Sales Growth: Up 13% for the full year. Vaccine Sales: GBP9 billion, down 3%. Free Cash Flow: Improved to GBP3.5 billion, excluding Zantac payments. Net Debt: Reduced to GBP13 billion. Share Buyback Program: Announced up to GBP2 billion over the next 18 months. 2025 Sales Growth Guidance: Expected to increase between 3% and 5%. 2025 Core Operating Profit and EPS Guidance: Expected to increase between 6% and 8%. Warning! GuruFocus has detected 4 Warning Signs with GSK. Release Date: February 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. GSK PLC (NYSE:GSK) reported an 8% increase in sales for 2024, reaching over GBP31 billion, driven by strong growth in specialty medicines. Core operating profit rose by 13% and core EPS increased by 12%, leading to two upgrades in guidance for 2024. The company announced a dividend increase to 61p per share and plans to pay 64p in 2025, reflecting strong financial performance. GSK PLC (NYSE:GSK) expects five new product approvals in 2025, including BLENREP for multiple myeloma and depomokimab for severe asthma. The company achieved 13 positive Phase III readouts in 2024, strengthening its R&D pipeline, particularly in oncology and respiratory immunology. Vaccine sales faced challenges due to external pressures in the U.S. and China, impacting Arexvy and Shingrix. The introduction of the Inflation Reduction Act is expected to have a GBP150 million to GBP200 million impact on HIV sales in 2025. GSK PLC (NYSE:GSK) adjusted its expectations for vaccine sales growth, anticipating a decrease in low single-digit percent in 2025. The company faces pricing and genericization pressures in its General Medicines portfolio, expecting sales to be broadly flat in 2025. There is significant speculation and potential changes to U.S. vaccine policy, contributing to short-term pressures on the vaccine market. Q: Can you provide more details on your expectations for Shingrix in China for 2025, given the current macroeconomic challenges? A: Emma Walmsley, CEO, mentioned that while there are short-term pressures acknowledged for 2024 and 2025, GSK remains ambitious about the long-term potential in China. The partnership with Joffe is aimed at navigating these short-term challenges, focusing on expanding in high-tier cities. Q: Within the mid-single-digit growth for HIV in 2025, are you anticipating much competitive impact from the launch of lenacapavir? A: David Redfern, President of Corporate Development, expressed confidence in continued growth for Apretude, highlighting the underdeveloped PrEP market in the U.S. and the strong efficacy of long-acting options. He noted that while lenacapavir may enter the market, it has limitations such as drug-drug interactions and nodules, which may not appeal to all patients. Q: Can you discuss the international opportunity for Arexvy and what factors might limit your ability to access these markets in 2025? A: Luke Miels, Chief Commercial Officer, stated that GSK is encouraged by the early uptake of Arexvy outside the U.S., with national immunization programs in several countries. The focus is on differentiating based on clinical data, and the market research indicates positive perceptions of Arexvy's efficacy and cost-effectiveness. Q: What are the expectations for peak sales of Arexvy and Shingrix, given the current headwinds? A: Emma Walmsley, CEO, reiterated that there is no change to the long-term ambitions for these assets. The short-term pressures are acknowledged, but the broader portfolio's strength and pipeline progress allow GSK to maintain its outlook for 2031, with significant contributions expected from specialty medicines and oncology. Q: How does GSK view the commercial environment for Arexvy in the U.S., particularly with Pfizer gaining market share? A: Luke Miels, Chief Commercial Officer, acknowledged the competitive pressure but emphasized GSK's focus on retail and preserving value. He noted that Arexvy holds a significant market share and that GSK is positioning itself for future opportunities, including potential revaccination and expanded indications. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
